Results 1 to 10 of about 15,810 (189)

Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales? [PDF]

open access: yesAntimicrob Agents Chemother
Ceftolozane/tazobactam is widely used against extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, yet FDA-approved dosing relies on intermittent infusion and a fixed 2:1 ratio that assumes adequate β-lactamase inhibition. Tazobactam’s faster
Pai MP   +7 more
europepmc   +3 more sources

Stability of Two Reserve Antibiotics in Elastomeric Pumps: Ceftazidime-Avibactam and Ceftolozane-Tazobactam. [PDF]

open access: yesAntibiotics (Basel)
Background/Objectives: Parenteral antibiotic therapy is indispensable in the treatment of several infections. The parenteral administration often leads to the need for prolonged hospitalization.
Erdmann J   +3 more
europepmc   +3 more sources

Ceftolozane/Tazobactam for Complex and Resistant Infections: Systematic Reviews of Comparative Efficacy Studies. [PDF]

open access: yesAntibiotics (Basel)
Introduction: The emergence and spread of multidrug-resistant infections has resulted in significant clinical and economic burdens. To address these infections, novel therapy combinations are needed.
Martin-Loeches I   +7 more
europepmc   +2 more sources

Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020-2024. [PDF]

open access: yesFront Cell Infect Microbiol
ObjectivesTo investigate the in vitro susceptibility of recent clinical Enterobacterales and Pseudomonas aeruginosa isolates collected in the Arabian Gulf region to ceftolozane/tazobactam, imipenem/relebactam, and comparator antimicrobial agents ...
Wise MG   +5 more
europepmc   +2 more sources

Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane/tazobactam treatment and evaluating therapeutic alternatives. [PDF]

open access: yesBMC Microbiol
Objectives Ceftolozane/tazobactam is a relevant option for treating multiresistant Pseudomonas aeruginosa, a major public health problem. Over a 14-month period, we studied the frequency of ceftolozane/tazobactam resistance development and mechanisms ...
Bientz L   +13 more
europepmc   +2 more sources

Trends in <i>Pseudomonas aeruginosa</i> In Vitro Susceptibility to Ceftolozane/Tazobactam in Latin America: SMART Surveillance Program, 2016-2024. [PDF]

open access: yesAntibiotics (Basel)
Objectives: To describe annual trends in the susceptibility of clinical isolates of Pseudomonas aeruginosa from Latin America to ceftolozane/tazobactam.
Wise MG   +6 more
europepmc   +2 more sources

Assessment of in vitro antimicrobial activities of ceftolozane/tazobactam and ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa clinical isolates. [PDF]

open access: yesBMC Infect Dis
Background Carbapenem resistant Pseudomonas aeruginosa (P. aeruginosa) is a global health concern that poses a challenge to treat in health care facilities.
Salem D   +5 more
europepmc   +2 more sources

Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry

open access: yesJournal of Global Antimicrobial Resistance, 2021
: Objectives: Ceftolozane/tazobactam is a cephalosporin/β-lactamase inhibitor combination with activity against Gram-negative bacilli. Here we report the use of ceftolozane/tazobactam in Canada using a national registry. Methods: The CLEAR registry uses
George G. Zhanel   +15 more
doaj   +1 more source

The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis

open access: yesTherapeutic Advances in Drug Safety, 2021
Objective(s): The aim of this study was to conduct a meta-analysis to assess the clinical safety of ceftolozane-tazobactam for the treatment of acute bacterial infections in adult patients.
Li-Ting Wang   +7 more
doaj   +1 more source

Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study

open access: yesJournal of Infection and Public Health, 2022
Background: Ceftolozane-tazobactam is an emerging ‎treatment for severe infections caused by multidrug-resistant (MDR) Pseudomonas ‎aeruginosa. However, limited ‎data support its use in bacteremia treatment.
Hakeam A. Hakeam   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy